Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
BIKEN to Map Out 5-Year Biz Plan, Eyes Collaboration for PIII: Director
The Research Foundation for Microbial Diseases of Osaka University, better known as BIKEN, is currently drawing up a five-year business plan through FY2019, which will include a numerical sales target in the final year, Director Koichi Yamanishi revealed on July…
To read the full story
Related Article
- BIKEN to Produce and Ship Same Amount of Seasonal Flu Vaccines as Last Season: Director Yamanishi
July 13, 2015
- “4-Company Oligopoly” on Seasonal Flu Vaccines Coming to an End, Era of Mega-Competition Coming to Japan: Dr Yamanishi of BIKEN
May 21, 2015
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
BUSINESS
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Santen’s Myopia Drug Ryjusea Wins Nod in Philippines
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…